Pre-clinical studies have identified nitroxyl (HNO), the reduced congener of nitric oxide (NO•), as a potent vasodilator which is resistant to tolerance development. The present study explores the efficacy of HNO in human blood vessels and describes, for the first time, a vasodilator for humans that is not susceptible to tolerance. Human radial arteries and saphenous veins were obtained from patients undergoing coronary artery graft surgery and mounted in organ baths. Repeated vasodilator responses to the HNO donor Angeli's salt (AS) and NO• donor glyceryl trinitrate (GTN) were determined. AS- and GTN-induced concentration-dependent vasorelaxation of both human radial arteries (AS pEC50: 6.5±0.2; −log M) and saphenous veins (pEC50: 6.7±0.1) with similar potency. In human radial arteries, GTN-induced relaxation was reduced by the NO• scavenger hydroxocobalamin (HXC; P<0.05) but was unaffected by the HNO scavenger L-cysteine. Alternately, AS was unaffected by HXC but was reduced by L-cysteine (5-fold shift, P<0.05). The sGC (soluble guanylate cyclase) inhibitor ODQ abolished responses to both AS and GTN in arteries and veins (P<0.05). Inhibition of voltage-dependent potassium channels (Kv channels) with 4-AP also significantly reduced responses to AS (pEC50: 5.5) and GTN, suggesting that the relaxation to both redox congeners is cGMP- and Kv channel-dependent. Critically, a concentration-dependent development of tolerance to GTN (1 and 10 μM; P<0.05), but not to AS, was observed in both saphenous veins and radial arteries. Like GTN, the HNO donor AS causes vasorelaxation of human blood vessels via activation of a cGMP-dependent pathway. Unlike GTN, however, it does not develop tolerance in human blood vessels.
Skip Nav Destination
Article navigation
Research Article|
April 24 2015
Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance
Karen L. Andrews;
*Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
Correspondence: Dr Karen Andrews (email karen.andrews@bakeridi.edu.au).
Search for other works by this author on:
Natalie G. Lumsden;
Natalie G. Lumsden
*Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
Search for other works by this author on:
Julie Farry;
Julie Farry
*Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
Search for other works by this author on:
Ann-Maree Jefferis;
Ann-Maree Jefferis
*Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
Search for other works by this author on:
Barbara K. Kemp-Harper;
Barbara K. Kemp-Harper
1
†Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia
Search for other works by this author on:
Jaye P. F. Chin-Dusting
Jaye P. F. Chin-Dusting
1
*Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
November 20 2014
Revision Received:
February 09 2015
Accepted:
March 02 2015
Accepted Manuscript online:
March 02 2015
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2015 Biochemical Society
2015
Clin Sci (Lond) (2015) 129 (2): 179–187.
Article history
Received:
November 20 2014
Revision Received:
February 09 2015
Accepted:
March 02 2015
Accepted Manuscript online:
March 02 2015
Citation
Karen L. Andrews, Natalie G. Lumsden, Julie Farry, Ann-Maree Jefferis, Barbara K. Kemp-Harper, Jaye P. F. Chin-Dusting; Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance. Clin Sci (Lond) 1 July 2015; 129 (2): 179–187. doi: https://doi.org/10.1042/CS20140759
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.